| Literature DB >> 2454578 |
D A Grimes1, D R Mishell, D Shoupe, M Lacarra.
Abstract
RU-486 is a synthetic progesterone antagonist that is abortifacient in early pregnancy. This trial evaluated the effectiveness and safety of a single 600 mg oral dose given to 50 healthy women less than or equal to 49 days from their last menstrual period. Efficacy was inversely related to the initial beta-subunit of human chorionic gonadotropin level, ranging from 100% at less than 5000 mIU/ml to 81% at greater than 20,000 mIU/ml (p less than 0.05). Uterine bleeding was the most serious side effect. However, the mean change in the hemoglobin value 14 days after treatment was -0.4 gm/dl, and no patient required blood transfusion. This regimen appears to be simple, effective, and safe.Entities:
Keywords: Abortifacient Agents--side effects; Abortion, Drug Induced; Abortion, Induced--complications; Americas; Biology; Developed Countries; Developing Countries; Endocrine System; Evaluation; Family Planning; Fertility Control, Postconception; Gonadotropins; Gonadotropins, Chorionic--analysis; Hemic System; Hemoglobin Level; Hormones; North America; Northern America; Physiology; Reproductive Control Agents; United States
Mesh：
Substances：
Year: 1988 PMID： 2454578 DOI： 10.1016/0002-9378(88)90361-4
Source DB: PubMed Journal: Am J Obstet Gynecol ISSN： 0002-9378 Impact factor: 8.661